Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma

Memorial Sloan Kettering Cancer Center754 enrolled

Overview

The purpose of this study is to determine if tumor cells can be detected in the peripheral blood and/or bone marrow of patients with melanoma.

Patients with melanoma can succumb to subclinical metastatic disease, not detectable at presentation by conventional physical examination, hematologic and biochemical screening, or radiologic evaluation. More intensive radiologic evaluation with CT or radioisotope scanning has not proven to be useful. What may be useful is a more sensitive method of staging melanoma patients at presentation, specifically evaluating them for subclinical systemic disease.

Study Type

OBSERVATIONAL

Enrollment

754

Conditions

Melanoma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: MSK Patients with histologically confirmed melanoma of any site and at least one of the following: * Primary tumor \> 4.0 mm thick (AJCC Stage IIB) * Clinically or histologically positive regional nodes (AJCC Stage III) * Any in transit disease (AJCC Stage III) * Any systemic metastases (AJCC Stage IV)

Locations (1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Outcomes

Primary Outcomes

Assess the sensitivity of RT-PCR to detect evidence of melanoma cells in bone marrow and/or peripheral blood and estimate sensitivity separately for each of the different stage groupings for melanoma

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.